Astaxanthin (2 mg) + Lycopene (1.8 mg) + D-Alpha-Tocopherol (10 IU) For The Treatment Of Skin Aging

United Laboratories

Status

Completed

Conditions

Wrinkles

Skin Aging

Treatments

Dietary Supplement: Placebo

Dietary Supplement: Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)

Study type

Interventional

Funder types

Industry

Identifiers

NCT03460860

RD2017-06 (Anti-Aging Study)

Details and patient eligibility

About

The purpose of this study is to determine the clinical efficacy of a combination of Astaxanthin (2 mg), Lycopene (1.8 mg), and d-alpha-Tocopherol (10 IU) in terms of its skin anti-aging properties. Specifically, the investigators aim to determine the increase in hydration levels of the skin, decrease in atypical skin pigmentation, and reduction of signs of photoaging, particularly facial fine lines.

Enrollment

100 patients

Sex

All

Ages

30 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy individuals age 30 to 60 years old
Fitzpatrick Skin Type I-IV
Crow's Feet Wrinkle Scale Class 1-2
Subjects willing to provide written informed consent

Exclusion criteria

Use of topical or oral anti-aging drug therapy 1 month prior to the study
History of allergy to cosmetics and anti-aging drugs
History of photosensitivity reactions
Any current or past medical condition, including seizures and stroke
History of pigmentation disorder such as but not limited to vitiligo and leukoderma
Immunocompromised state
Pregnant or lactating (pregnancy kit will be used to check)
Patients who have undergone laser, radiofrequency, peeling, and other procedural therapies for anti-aging in the month prior to the study.
Patients with current inflammatory or infectious skin disease on the face, or history of such in the month prior to the study.
Patients taking OCDs and other photosensitizing drugs (e.g. tetracycline).
Not willing to provide informed consent